|
WO2008108993A1
|
|
Ectopic, orthotopic model for revascularization and tumor assessment
|
|
CA2628837A1
|
|
Cd40 ligand fusion protein vaccine
|
|
AU2006234897A1
|
|
Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
|
|
EP1756165A2
|
|
Tissue-specific imaging and therapeutical agents targeting proteins expressed on lung endothelial cell surface
|
|
CA2572451A1
|
|
Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature
|
|
EP1755686A2
|
|
Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
|
|
WO2005058950A2
|
|
Methods for generating immunity to antigen
|
|
WO2005042564A1
|
|
Flagellin fusion proteins as adjuvants or vaccines and methods of use
|
|
US2005032728A1
|
|
Tumor suppression through bicistronic co-expression of p53 and p14ARF
|
|
US2004053317A1
|
|
Gene segregation and biological sample classification methods
|
|
AU3120401A
|
|
Genetically engineered tumor cell vaccines
|
|
AU3300401A
|
|
Myeloid colony stimulating factor and uses thereof
|
|
AU3667299A
|
|
Reduced complexity nucleic acid targets and methods of using same
|
|
EP1007739A2
|
|
Selection of pcr primer pairs to amplify a group of nucleotide sequences
|
|
BR9808866A
|
|
Retinoic molecules related to the inhibition of endothelin-1 overproduction in diseases
|
|
WO9727876A1
|
|
Immunotherapy sensitization of cancer therapy
|
|
US6054467A
|
|
Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
|
|
AU2462895A
|
|
Enhancing the sensitivity of tumor cells to therapies
|
|
US5681562A
|
|
Lymphokine gene therapy of cancer
|
|
EP0721351A1
|
|
Haplotype-matched cytokine-secreting cells and methods of using to stimulate an immune response
|
